- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02440555
Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose (Sainté Diabète)
Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose Compared to Current Screening in the Priority Health Area of Saint-Etienne and the Sainté Diabète Network.
Type 2 diabetes is the chronic disease with the most important development in France, and particularly in the Saint-Etienne area due to his specific population.
Different studies showed the interest of screening targeted on high risk population to reduce cardiovascular risks and mortality.
The current screening recommandation is an opportunist targeted screening on population older than 45 years with risk factors by a fasting glucose every 3 years, and a communautaire screening targeted on population older than 45 years suffering precarity with or without risk factors by capillary blood glucose or fasting glucose.
The objective of the Sainté Diabete network is to optimize the screening of diabetics, their follow-up and their treatments. Using a self-administered questionnaire during a medical visit could be a simple, cheap and efficient tool to detect diabetics as soon as possible.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Saint-etienne, France, 42055
- Chu Saint-Etienne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Man or woman
- 45 years or older
- Signed informed consent
Exclusion Criteria:
- fasting glucose performed in the last 2 years
- diabetes history
- not living in Saint-Etienne
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients included
fulfill the self-administered questionnaire.
|
Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of detection of type 2 diabetes
Time Frame: Day 1 (inclusion day)
|
To evaluate the sensitivity (true positive) of detection of type 2 diabetes by a self-administered questionnaire performed in a pharmacy or a hospital compared to capillary blood glucose measurements in the same population from the priority health area of Saint-Etienne.
|
Day 1 (inclusion day)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity of detection of type 2 diabetes
Time Frame: Day 1 (inclusion day)
|
To evaluate the specificity (true negative) of detection of type 2 diabetes by a self-administered questionnaire performed in a pharmacy or a hospital compared to capillary blood glucose measurements in the same population from the priority health area of Saint-Etienne
|
Day 1 (inclusion day)
|
To evaluate the cost of the targeted screening and the screening accessibility to population from the priority health area of Saint-Etienne
Time Frame: Month 2
|
Month 2
|
|
To evaluate the numbers of patients screened by self-administered questionnaire and diagnosed as diabetics using fasting glucose.
Time Frame: Month 2
|
Month 2
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Christophe BOIS, Pr, Université de Saint-Etienne
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBS2014-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on fulfill the self-administered questionnaire
-
Jewish General HospitalWithdrawnQuality of Life | Health, Subjective | Mental Health | MuseumCanada
-
University Hospital, LilleFondation Santé RoquetteCompleted
-
Alaa Mohammed YehiaCompletedMolar Incisor Hypomineralization | Dental Enamel HypoplasiaEgypt
-
University Hospital, LilleFondation Santé RoquetteUnknown
-
Central Hospital, Nancy, FranceCompletedAtopic DermatitisFrance
-
University Hospital, BordeauxRecruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisFrance
-
Centre Hospitalier Charles Perrens, BordeauxRégion Nouvelle Aquitaine; Regional Health Agency New AquitaineNot yet recruitingCovid19 | Work-Related Condition | Work-Related Stress Disorder | Personnel, Hospital
-
University Hospital, MontpellierTerminated
-
Istanbul UniversityIstanbul Physical Medicine and Rehabiltation Training and Research HospitalCompletedNeck Pain | Disability Physical | Ergonomic FactorsTurkey